Evidence map›Paper›PMID 42943554›Full record

ArticleMicroorganisms2026

Shaojun Li, Wenxiang Sheng, Yang Yang, Peixuan Li, Qing Su, Zhongtian Shi, Junyu Zhou, Heng Yuan, Sifang Feng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shaojun LiDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Wenxiang ShengDepartment of Physiology and Pathophysiology, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an 710049, China.
Yang YangDepartment of Physiology and Pathophysiology, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an 710049, China.
Peixuan LiDepartment of Physiology and Pathophysiology, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an 710049, China.ORCID 0009-0003-2877-063X
Qing SuDepartment of Physiology and Pathophysiology, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an 710049, China.ORCID 0009-0001-4207-3983
Zhongtian ShiDepartment of Physiology and Pathophysiology, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an 710049, China.
Junyu ZhouInstitute of Advanced Clinical Medicine, Peking University, Beijing 100191, China.ORCID 0000-0001-5931-1477
Heng YuanDepartment of Physiology and Pathophysiology, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an 710049, China.
Sifang FengDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.

Funding

Shaanxi Province Natural Science Basic Research Program 2024JC-YBMS-768Shaanxi Province Natural Science Basic Research Program 2025JC-YBMS-960Shaanxi Provincial Postdoctoral Scientific Research Funding Project 2025BSHSDZZ035the Central Universities under Grant Xi'an Jiaotong University xtr012026114the Central Universities under Grant Xi'an Jiaotong University xzy012024117
6 · The paper itself

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. Although gut microbiota dysbiosis and aberrant bile acid metabolism are central to MASLD pathogenesis, the critical keystone species and precise molecular mechanisms remain elusive. Here, we performed an integrated analysis of 14 public 16S rRNA datasets (275 controls, 352 patients), combining multi-method differential abundance screening, machine learning, and network analysis to pinpoint MASLD-specific microbial signatures. We further validated the therapeutic potential of candidate secondary bile acids (SBAs) in a HepG2 steatosis model. MASLD patients displayed significantly reduced microbial diversity and a distinct community structure.

Indexed as

AMPK signalingBifidobacterium longumgut microbiotametabolic dysfunction-associated steatotic liver disease (MASLD)microbial co-occurrence networksecondary bile acidsTGR5

Identifiers

PMID42943554
PMCPMC13707802

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.